Another commenter recommended CMS clarify the types of data that would be included in the ASM preliminary eligibility notification
Because there is no combination-level trial, this timeline is a synthesis of the individual-peptide literature and the protocols own structure treat it as a framework for observation, not a guarantee
Clinicians prescribing BPC-157 should document the following in the medical record: the off-label nature of the prescription, the absence of human clinical trial data, the FDA's position on compounded BPC-157, the patient's prior treatment history with approved therapies, and the patient's written informed consent
The results generally show reduced neurological deficit scores and faster behavioral recovery in treated animals
One full syringe
However, until larger controlled studies show measurable and reproducible improvements in fertility, I do not feel that these supplements are worth the money or the risk of potentially negative side effects